Last reviewed · How we verify
NCT06021002
Nasal Immune Challenge Study
NA trial testing R848 in Innate Inflammatory Response in 24 participants. Status unknown.
30 September 2024
Quick facts
| Lead sponsor | Cambridge University Hospitals NHS Foundation Trust |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 9 August 2022 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- R848 — full drug profile →
- Saline
Conditions studied
- Innate Inflammatory Response — all drugs for Innate Inflammatory Response →
- Asthma — all drugs for Asthma →
- Nasal Allergy — all drugs for Nasal Allergy →
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Who can join
18 and older, any sex, with Innate Inflammatory Response or Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Respiratory viral infections cause significant illness, especially in vulnerable individuals and is a topic of immense significance during the current COVID-19 global pandemic. Respiratory diseases such as asthma involve inflammation of the airways and viruses are a major cause of asthma attacks. The nose is easier to access than the lungs but has similar cells and is therefore useful to study immune responses throughout the respiratory tract. Rather than study the effects of a live virus on the immune system, it is possible to give a component or mimic of a virus to simulate an infection in a similar but more straightforward manner, without causing disease. In this study we will use a nasal spray containing a sterile substance called Resiquimod (also called R848) to mimic a viral infection. Resiquimod does not contain any living organisms and therefore there is no possibility of developing a real infection. Resiquimod works by binding to receptors in cells that line the inside of the nose (epithelial cells) as well as cells that can fight infection (immune cells). These cells respond to Resiquimod and cause mild inflammation in the nose, similar to a mild cold. We can then take samples to measure this response and investigate how it differs between individuals. This will help us better understand how the human immune system responds to viruses, and which cells and molecules the body uses to defend itself against infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Drug Delivery Systems for Resiquimod to Control Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
He Y, Yeo Y. · · 2026 · PMID 41804092 · DOI 10.1002/wnan.70052
Verify or expand the search:
- PubMed search for NCT06021002
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Innate Inflammatory Response
Currently open trials in the same condition.
- NCT06092463 — The Intestinal Innate Immune System in Newborns. Development and Inflammation in Health and Disease · recruiting
Other Cambridge University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
- NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
- NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
- NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
- NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06021002 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
- Last refreshed: 1 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06021002.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing